FDA grants Breakthrough Therapy Designation to Hemab Therapeutics’ sutacimig for Glanzmann thrombasthenia. Discover what this means for bleeding disorder treatment.
Kyowa Hakko’s Eyemuse postbiotic enters children’s gummies with Zen Nutrients. We analyse the clinical evidence, regulatory gaps, and market implications. Read more.
Kenox Pharmaceuticals announces clinical manufacturing readiness for inhaled and nasal drug products. What this means for OINDP development timelines and IVBE strategy.
Zealand Pharma advances petrelintide toward Phase 3 after strong Phase 2 obesity trial results. Discover what this means for the evolving weight-loss drug market.
Alnylam Pharmaceuticals partners with Tenaya Therapeutics to discover RNAi targets for cardiovascular disease. Read the analysis behind this biotech collaboration.
CordenPharma Colorado expands peptide development capacity with a new Boulder lab facility. Discover what this means for peptide drug manufacturing.
FDA clears Vasomune Therapeutics’ IND for pegevongitide in severe burn resuscitation. Explore what this Tie2 therapy could change for vascular leak treatment.
Can LYMPHIR boost CAR-T therapy success in lymphoma? Discover what early trial data reveals about immune microenvironment targeting.
Azenta acquires UK Biocentre for £20.5M to expand European biorepository capabilities. Discover what this means for life sciences research infrastructure.
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.